TME Pharma Extends Loans by 12 Months and Secures Cash Flow Until 2027
TME Pharma announces in a press release that certain lenders have agreed to extend the duration of their loans by an additional 12 months, ensuring its cash flow until the second quarter of 2027. This extension concerns about 93% of the loans taken out in May and August 2025.
An agreement has been reached with lenders who participated in the May and August 2025 funding rounds to extend the duration of their loan contracts by an additional 12 months, bringing the total amount to approximately 2.06 million euros. In exchange for this extension, the duration of the warrants has been extended until December 31, 2030. Lenders received 30% additional warrants at the same exercise prices as the existing ones (0.10 € and 0.11 € respectively). These new warrants are subject to a lock-up period until January 1, 2029, unless the share price reaches or exceeds 0.25 €. TME Pharma will also repurchase the bonds from holders who do not wish to extend their duration for an amount of 163,562.50 € including interest.
Strategic Restructuring Under New CEO
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Under the leadership of the new CEO, Diede van den Ouden, who joined in June 2025, TME Pharma is undergoing a strategic restructuring aimed at freeing up financial resources necessary to unlock the value of its two main assets, NOX-A12 and NOX-E36. The management states that they can now accelerate discussions with their partners to optimize the value of these compounds. No new warrants issued from the May and August 2025 programs have been exercised to date, and no new shares have been issued in 2025 and 2026.
Related
SectorIndustrie Pharmaceutique et Biotechnologie›Biotechnologie
Context
Period
Period: 2025
Key reported figures
Net income: -3,3M€
Guidance from the release
En tant qu'actionnaire et administrateur, je reste optimiste quant à l'avenir de TME Pharma.
Risks mentioned
Les capitaux propres au 31 décembre 2025 sont désormais négatifs de 1,6 million d'euros.
L'absence de chiffre d'affaires génère des incertitudes financières.
Opportunities identified
TME Pharma se concentre sur la conclusion d'accords de licence pour NOX-A12 et NOX-E36.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
